Drugs / Vodobatinib
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03445338 | Apr 2018 → Dec 2019 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03316820 | Oct → Nov 2017 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02970019 | Mar 2017 → May 2019 | Parkinson disease | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02629692 | Jun 2016 → Jan 2025 | chronic myeloid leukemia | Sun Pharma Advanced Research Company Limited | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03655236 | Feb 2019 → Apr 2024 | Parkinson disease | Sun Pharma Advanced Research Company Limited | Terminated | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03996460 Comparator | Sep 2019 → Apr 2024 | Lewy body dementia | Georgetown University | Terminated | No outcome recorded |
| — | NCT07517315 Background | — | chronic myeloid leukemia | Sun Pharma Advanced Research Company Limited | Temporarily not available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
All press releases naming this drug 3 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vodobatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02629692 ↗ |
| Known as | K0706 | “Part A: Oral Vodobatinib (K0706) capsules in single ascending doses.” NCT02629692 ↗ |
| Known as | Sco-088 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4130229 ↗ |
| Action | Inhibit | “a novel selective BCR::ABL1 TKI” PMID 39929221 ↗ Feb 2025 |
| Modality | Small molecule | — CHEMBL4130229 ↗ |
| Route | Oral | “Patients self-administered oral vodobatinib (12-240 mg) once per day for each 28-day treatment cycle and for up to 60 months (ie, 65 cycles) unless patient discontinuation due...” PMID 39929221 ↗ Feb 2025 |
| Target | ABL1 | “a novel selective BCR::ABL1 TKI” PMID 39929221 ↗ Feb 2025 |
| Target | BCR | “a novel selective BCR::ABL1 TKI” PMID 39929221 ↗ Feb 2025 |